Millipore Sigma Vibrant Logo

PF074 VEGF₁₆₅, Human, Recombinant

VEGF₁₆₅, Human, Recombinant : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.

Synonymes: Vascular Permeability Factor

PF074
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Purity
      ≥95% by SDS-PAGE
      Description
      OverviewRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions.
      Catalogue NumberPF074
      Brand Family Calbiochem®
      SynonymsVascular Permeability Factor
      References
      ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Leung, D.W., et al. 1989. Science 246, 1306.
      Product Information
      FormLyophilized
      FormulationCarrier free.
      PreservativeNone
      Quality LevelMQ100
      Applications
      Erreur de configuration des données. Pagelet <collection_feature_application_id-PROLIF> non trouvé.
      Application NotesProliferation Studies
      Biological Information
      Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
      Purity≥95% by SDS-PAGE
      Physicochemical Information
      ContaminantsEndotoxins: ≤100 pg/µg VEGF
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage -20°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      PF074 0

      Documentation

      VEGF₁₆₅, Human, Recombinant FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Références bibliographiques

      Aperçu de la référence bibliographique
      Hashimoto, G., et al. 2002. J. Biol. Chem. In Press.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Leung, D.W., et al. 1989. Science 246, 1306.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision16-September-2008 RFH
      SynonymsVascular Permeability Factor
      ApplicationProliferation Studies
      DescriptionRecombinant, human VEGF165 (a 165 amino acid splice varian of VEGF) expressed under serum-free conditions in Spodoptera frugiperda cells and purified via a proprietary sequential chromatrography methods. VEGF165 binds to the connective tissue growth factor (CTGF) and the resulting complex has no angiogenic activity. Degradation of CTGF by matrix metalloproteinases results in VEGF-induced angiogenesis during embryonic development and pathological disease states. The recombinant disulfide-linked homodimeric human VEGF is glycosylated and, thus, migrates as a ~42 kDa protein in SDS-PAGE under non-reducing conditions. Useful for proliferation assays; titrate for optimal results with individual cell types.
      FormLyophilized
      FormulationCarrier free.
      Purity≥95% by SDS-PAGE
      ContaminantsEndotoxins: ≤100 pg/µg VEGF
      Biological activityEC₅₀ of 1-6 ng/ml as determined by the dose dependent proliferation of human ubilical vein epithelial cells (HUVEC)
      SolubilityReconstitute lyophilized product in sterile PBS containing at least 0.1% human serum albumin or bovine serum albumin to ≥ 10 µg/ml. Make further dilutions in PBS, 0.1% BSA, HSA, or other carrier protein.
      PreservativeNone
      Storage Avoid freeze/thaw
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesHashimoto, G., et al. 2002. J. Biol. Chem. In Press.
      Soker, S., et al. 1998. Cell 92, 735.
      Kroll, J. and Waltenberger, J. 1997. J. Biol. Chem. 272, 32521.
      Klagsbrun, M. and Soker, S. 1993. Current Biology 3, 699.
      Senger, D., et al. 1993. Cancer and Metastasis Rev. 12, 303.
      Brown, L., et al. 1992. Kidney International 42, 1457.
      Dvorak, H., et al. 1991. J. Exp. Med. 174, 1275.
      Conn, G., et al. 1990. PNAS 87, 1323.
      Leung, D.W., et al. 1989. Science 246, 1306.